Gabify

Gabify, based in Noida, India, specializes in innovative early screening solutions for speech and neurodevelopmental disorders, utilizing AI to enhance access to timely diagnoses and interventions. Founded in 2023, Gabify offers AI-powered screening solutions for developmental disorders, targeting families in underserved regions of India. The company recently secured USD 175,000 in pre-seed funding led by Inflection Point Ventures on April 2, 2026, to enhance its product offerings. Gabify has executed one deal to date.

Gabify delivers innovative solutions for early screening of speech and neurodevelopmental disorders via its flagship product, Neurolens. This AI-driven platform allows parents, therapists, and educators to conduct video uploads and screening tests for analyzing speech patterns and behavioral markers. The service primarily assists families with young children in India, connecting them to therapy centers and improving care quality. Gabify's revenue model is based on a subscription system for its Neurolens services.

Families and educational institutions pay for the screening services, while therapy centers subscribe to access the platform. Revenue is generated through recurring subscription fees from both direct-to-consumer sales and partnerships with organizations focused on neurodevelopmental care. Following the recent funding round, Gabify plans to enhance its platform and accelerate development. The company aims to launch new features and expand its market reach beyond India.

The funding will be allocated towards the development process, enabling Gabify to address more families and improve its AI-driven solutions.